8-K: ANI Pharmaceuticals Loses Royalty Dispute, Awarded No Damages in CG Oncology Lawsuit

A jury has ruled against ANI Pharmaceuticals, awarding no damages in its lawsuit against CG Oncology regarding a 5% royalty on cretostimogene sales.

Summary

• ANI Pharmaceuticals, Inc. (the Company) commenced a civil action against CG Oncology, Inc. in the Superior Court of the State of Delaware on March 4, 2024.
• The Company's complaint alleged that under a November 15, 2010 agreement, CG Oncology was liable to pay a running royalty of 5% of the worldwide net sales of cretostimogene.
• CG Oncology wrongfully repudiated its royalty obligation to the Company in February 2024.
• On June 2, 2025, CG Oncology filed five motions for summary judgment seeking dismissal of all the Company's claims, including breach of royalty payment, breach of good faith, and unjust enrichment.
• Also on June 2, 2025, the Company filed a motion for partial summary judgment seeking dismissal of CG Oncology's counterclaims for unenforceability of the royalty payment provision, breach of good faith, breach of confidentiality, and trade secret misappropriation.
• On July 16, 2025, the court granted CG Oncology's motion for partial summary judgment on its Brulotte counterclaim and affirmative defense, but allowed the Company's counterclaim for unjust enrichment to proceed.
• The court also granted the Company's motion for partial summary judgment, dismissing CG Oncology's breach of confidentiality and trade secret misappropriation claims.
• A jury trial commenced in Delaware Superior Court on July 21, 2025.
• On July 29, 2025, the jury returned a verdict finding that the unenforceability of the royalty payment provision did not materially adversely affect the economic or legal substance of the transactions for the Company.
• The jury awarded no damages to the Company on its unjust enrichment counterclaim.

Sentiment

Score: 2

Explanation: The verdict is highly negative for ANI Pharmaceuticals as it lost its claim for a 5% royalty on worldwide net sales and was awarded no damages, representing a significant loss of potential future revenue.

Positives

• The court granted the Company's motion for partial summary judgment, dismissing CG Oncology's counterclaims for breach of confidentiality and trade secret misappropriation.

Negatives

• The jury found that the unenforceability of the royalty payment provision in the November 2010 Agreement did not materially adversely affect the economic or legal substance of the transactions contemplated thereby for the Company.
• The jury awarded no damages to the Company on its unjust enrichment counterclaim, despite the Company's claim for a 5% running royalty on worldwide net sales of cretostimogene.

Risks

• The Company expects to challenge the jury's verdict through post-trial motions and/or an appeal, which may incur additional legal costs and prolong the dispute.

Future Outlook

ANI Pharmaceuticals expects to challenge the jury's verdict through post-trial motions and/or an appeal.

Management Comments

• We expect to challenge this verdict through post-trial motions and/or an appeal.

Industry Context

Royalty and intellectual property disputes are common in the pharmaceutical industry, often arising from licensing agreements or technology transfers. The outcome of such litigation can significantly impact a company's future revenue streams and valuation, particularly when it involves a potential percentage of worldwide net sales of a product.

Legal Proceedings

• ANI Pharmaceuticals commenced a civil action against CG Oncology in the Superior Court of the State of Delaware on March 4, 2024, alleging CG Oncology was liable for a 5% running royalty on worldwide net sales of cretostimogene under a November 15, 2010 agreement, and that CG Oncology wrongfully repudiated this obligation in February 2024.
• On June 2, 2025, CG Oncology filed five motions for summary judgment seeking dismissal of ANI's claims (breach of royalty payment provision, breach of good faith performance, breach of the implied covenant of good faith, and unjust enrichment).
• On June 2, 2025, ANI Pharmaceuticals filed a motion for partial summary judgment seeking dismissal of CG Oncology's counterclaims (unenforceability of the royalty payment provision under Brulotte, breach of good faith performance, breach of confidentiality, and trade secret misappropriation).
• On July 16, 2025, the court granted CG Oncology's motion for partial summary judgment on its Brulotte counterclaim and affirmative defense, but allowed ANI's unjust enrichment counterclaim to proceed.
• On July 16, 2025, the court also granted ANI's motion for partial summary judgment, dismissing CG Oncology's breach of confidentiality and trade secret misappropriation claims.
• A jury trial commenced on July 21, 2025, in Delaware Superior Court.
• On July 29, 2025, the jury returned a verdict finding that the unenforceability of the royalty payment provision did not materially adversely affect the economic or legal substance of the transactions for ANI, and awarded no damages to ANI on its unjust enrichment counterclaim.

Stakeholder Impact

• Shareholders: Potential negative impact due to the loss of a significant future revenue stream (5% royalty on worldwide net sales of cretostimogene) and ongoing legal costs associated with challenging the verdict.

Next Steps

• ANI Pharmaceuticals to challenge the verdict through post-trial motions.
• ANI Pharmaceuticals to potentially file an appeal.

Key Dates

Recommendation

The jury's verdict, awarding no damages and effectively denying the 5% worldwide net sales royalty on cretostimogene, represents a substantial loss of potential future revenue for ANI Pharmaceuticals. This outcome significantly diminishes the company's financial outlook related to this asset and introduces further uncertainty and legal costs as the company pursues post-trial motions and appeals. This negative development warrants a sell recommendation for investors.

Keywords

ANI Pharmaceuticals, CG Oncology, cretostimogene, royalty dispute, litigation, pharmaceutical, intellectual property, unjust enrichment, Delaware Superior Court, 8-K filing